MIV Therapeutics Invests in Additional Equipment and Scientific Personnel In Reflection of R&D Program Expansion
28th Sep 2005, 11:33 GMT
MIV Therapeutics, a developer of next-generation biocompatible stent coatings and drug delivery technologies, has expanded its comprehensive innovation and development program to improve advanced vascular stents and internal drug-delivery systems.
Latest news from Angiography/ Cardiac Cath News from StratCenter.com:
- Thinking Systems Releases Enhanced PET-CT Functions for Its ThinkingPACS
- Tallahassee Memorial Hospital at the Forefront in Treatment of Heart Attack Patients
- Preliminary Long-Term Clinical Data Show Promising Results for the CYPHER Sirolimus-eluting Coronary Stent in Patients With Multi-Vessel Disease